Differential expression of serum GBP-28, NBP-Cyc 3 and TIMP-1 complicates pregnancy in hypertensive disorder pregnancy.The current study is aimed at analyzing the correlation and differential expression of three entities namely, TIMP metallopeptidase inhibitor-1 (TIMP-1), a glycoprotein, serum adipokine (GBP-28), an amino acid protein and neuroendocrine basic polypeptide NBP-cystatin3 (NBP-Cyc 3) in HDP (Hypertensive Disorders complicating Pregnancy).
Bioinformatics approach to understand the mode of microbial pathogenesis of Chlamydia trachomatis and their implications in gynecologic malignancy.The current study reports a wide range of C. trachomatis proteins that target the cellular as well as sub-cellular components of the host in gynecologic malignancy.
Modulation of host immune status by Cryptococcus co-infection during HIV-1 pathogenesis and its impact on CD+4 cell and cytokines environmentCryptococcus infection is the second most common opportunistic infection in HIV patients with an increased rate of morbidity and mortality. Altered immune system during HIV- Cryptococcus co-infection is yet to be explored by laboratory. This study evaluates pro- and the anti-inflammatory cytokines in HIV patients with Cryptococcus co-infection and correlate them with CD4+T cell counts as well as viral loads before the initiation of drug therapy.
Targeted contrast agent for imaging-guided surgery for extensive cancer treatmentsBy injecting a contrast agent and illuminating with near-infrared light, cancer cells will show a fluorescent reaction, help to clearly distinguish normal cells and cancer cells, facilitate surgery, and remove tumor clearly.
Reagent for Monitoring Cancer Therapy Resistance in Real-Time and Extensive Cancer Screening (Tumor Signal-Liquid Biopsy)Therapy resistances in cancer are often undetectable or detected too late by current methods (CT scan & liquid biopsy), cause patient death and huge expenses in the medical and economic systems! The tumor signal transduction oncoproteins insides tumor cells control tumor survival. With the world‘s first invention “Tumor Signal-Liquid Biopsy” (to assay the tumor signal transduction activity in blood from cancer patients), our product (DxSure) monitors the therapy resistances of all cancer types and all therapy methods in real-time. Our product can help cancer patients get correct drug in time.